PDUFA VII Will Fund Pregnancy Postmarket Safety Update, Sentinel Upgrades, REMS Standardization
Executive Summary
US FDA will incorporate performance goals for reviewing REMS methodological approaches and study protocols as part of PDUFA reauthorization.
You may also be interested in...
Antiretroviral Pregnancy Registry Lights Way For Pregnancy Postmarketing Studies
The 30+ year-old program, which monitors prenatal exposure to 164 drugs, should be the template for other efforts, US FDA officials say, because disease-based pregnancy registries ‘have a better track record.’
FDA Real-Time Surveillance Not Practical For All Drugs, CDER’s Safety Surveillance Chief Says
Gerald Dal Pan indicated in an interview that the agency's safety systems as now constituted are generating the data needed and that so-called real-time surveillance, which is in place for COVID-19 vaccines and therapeutics, is not practical for all approved products.
Pregnancy Safety Could Transform US FDA Sentinel Role In Post-Marketing Studies
As part of the new user fee agreement, FDA will develop its active surveillance safety network into a reliable tool for post-marketing pregnancy safety studies. A review of the opportunities to use the Sentinel system more broadly shows that could be an important enhancement for industry.